Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

BIO-RAD LABORATORIES, INC.

(BIO)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nyse
10/18/2021 10/19/2021 10/20/2021 10/21/2021 10/22/2021 Date
727.17(c) 732.76(c) 747.06(c) 759.85(c) 753.58 Last
102 221 76 076 74 981 102 513 109 770 Volume
+0.79% +0.77% +1.95% +1.71% -0.83% Change
More quotes
Estimated financial data (e) (USD)
Sales 2021 2 845 M - -
Net income 2021 486 M - -
Net cash position 2021 1 174 M - -
P/E ratio 2021 46,8x
Yield 2021 -
Sales 2022 2 862 M - -
Net income 2022 481 M - -
Net cash position 2022 1 643 M - -
P/E ratio 2022 47,3x
Yield 2022 -
Capitalization 22 316 M 22 316 M -
EV / Sales 2021 7,43x
EV / Sales 2022 7,22x
Nbr of Employees 8 000
Free-Float 70,8%
More Financials
Company
Bio-Rad Laboratories, Inc. manufactures and supplies the life science research, healthcare, analytical chemistry and other markets with a range of products and systems used to separate chemical and biological materials and to identify, analyze and purify their components. The Company operates through two segments: Life Science and Clinical Diagnostics. Life Science segment markets and develops, manufactures and... 
More about the company
Ratings of Bio-Rad Laboratories, Inc.
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
C+
More Ratings
All news about BIO-RAD LABORATORIES, INC.
10/19BIO RAD LABORATORIES : Commissioner's Decision 1590 – Inputs, Outputs And Everything..
AQ
10/15BIO RAD LABORATORIES : Rad to Report Third-Quarter 2021 Financial Results, Thursday, Octob..
BU
10/04BIO-RAD LABORATORIES, INC. : Change in Directors or Principal Officers (form 8-K)
AQ
10/04Bio-Rad Laboratories, Inc. Announces Executive Changes, Effective January 4, 2022
CI
08/31BIO RAD LABORATORIES : Rad to Participate in the 2021 Virtual Wells Fargo Healthcare Confe..
BU
08/0310X GENOMICS : After Intense Patent Litigation Bio-Rad And 10x Genomics Settle Through Cro..
AQ
07/30BIO RAD LABORATORIES : Management's Discussion and Analysis of Financial Condition and Res..
AQ
07/30Tranche Update on Bio-Rad Laboratories, Inc.'s Equity Buyback Plan announced on Novembe..
CI
07/30SECTOR UPDATE : Health Care Stocks Scratching Out Small Advance Just Ahead of Friday Close
MT
07/30SECTOR UPDATE : Health Care Stocks Posting Modest Friday Advance
MT
07/30BIO RAD LABORATORIES : Wells Fargo Adjusts Price Target on Bio-Rad Laboratories to $930 Fr..
MT
07/29BIO RAD LABORATORIES : Rad Reports Second-Quarter 2021 Financial Results (Form 8-K)
PU
07/29BIO-RAD : Q2 Earnings Snapshot
AQ
07/29BIO RAD LABORATORIES : Q2 Adjusted Earnings More Than Double as Revenue Improves
MT
07/29BIO-RAD LABORATORIES, INC. : Results of Operations and Financial Condition, Financial Stat..
AQ
More news
News in other languages on BIO-RAD LABORATORIES, INC.
2020L'ombre d'un doute
2020EN DIRECT DES MARCHES : Peugeot, Orange, Verallia, Solocal, Valneva, easyJet, Cineworld, H..
2020AKTIE IM FOKUS : Sartorius können Rekordhoch nicht verteidigen - Verluste
2019Paris attend des clarifications
2019Bourse - sartorius stedim biotech gagne 1,9%, jpmorgan ayant entamé le suivi du titre à..
More news
Analyst Recommendations on BIO-RAD LABORATORIES, INC.
More recommendations
Chart BIO-RAD LABORATORIES, INC.
Duration : Period :
Bio-Rad Laboratories, Inc. Technical Analysis Chart | BIO | US0905722072 | MarketScreener
Technical analysis trends BIO-RAD LABORATORIES, INC.
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 4
Last Close Price 753,58 $
Average target price 771,25 $
Spread / Average Target 2,34%
EPS Revisions
Managers and Directors
Norman D. Schwartz Chairman, President & Chief Executive Officer
Ilan Daskal Chief Financial Officer & Executive Vice President
Andrew J. Last Chief Operating Officer & Executive Vice President
Jeffrey L. Edwards Independent Director
Gregory K. Hinckley Lead Independent Director
Sector and Competitors
1st jan.Capi. (M$)
BIO-RAD LABORATORIES, INC.28.15%22 471
ABBOTT LABORATORIES14.21%221 691
MEDTRONIC PLC3.85%163 718
BECTON, DICKINSON AND COMPANY-1.50%70 784
HOYA CORPORATION21.65%55 133
DEXCOM, INC.53.66%54 963